Pliant reports positive Phase 2a data for bexotegrast 320 mg in PSC; fibrosis markers improved

PLIANT THERAPEUTICS, INC.

Bexotegrast 320 mg well tolerated with no drug-related severe or serious adverse events; 96% of 27 patients completed 12 weeks.
Reduced ELF and PRO-C3 levels relative to placebo at Week 12, indicating antifibrotic activity.
Stabilized alkaline phosphatase and showed improved hepatocyte function and bile flow on contrast MRI vs placebo.
Statistically significant reduction in itch Numerical Rating Scale at Week 12 for the 320 mg dose.
Company plans to share data with regulatory authorities to discuss potential registration path.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.